REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc., trading under the ticker TZAC, filed an 8-K with the Securities and Exchange Commission on July 24, 2020, marking a notable filing in the SPAC landscape for that year. The company operates in the clinical-stage biopharmaceutical sector, with a focus on central nervous system and other therapeutic areas. The 2020 filing reflects activity during a period of heightened SPAC deal flow across healthcare and life sciences, as blank-check vehicles sought targets in the pharmaceutical space. The accession number on record is 0001104659-20-086490. For complete filing details, sponsor information, deal history, and real-time SPAC analytics on TZAC and hundreds of other vehicles, sign up for full data access at SpacDesk.